title: Apolipoprotein B level in patients with type 2 diabetes who achieved goal of low density lipoprotein cholesterol and non-high density lipoprotein cholesterol.
abstract: OBJECTIVE
  To demonstrate an apolipoprotein B (apo B) level in type 2 diabetic patients who achieved goal of low density lipoprotein cholesterol (LDL-c) and non-high density lipoprotein cholesterol (non-HDL-c). To identify the percentage of type 2 diabetes patients who achieved goal of apo B level.
  
  
  METHODS
  A cross-sectional study was carried out from 1 October to 31 December 2008. Type2 diabetes patients who attended at diabetes clinics in the Phramongkutklao hospitals have determined the risk for develop cardiovascular diseases (CVD) and set up the goal for lipid level according to consensus statement from the American Diabetes Association (ADA) and the American College of Cardiology (ACC) foundation. Blood test for apo B will be done only the patients who achieved goal of LDL-c and non-HDL-c.
  
  
  RESULTS
  133 of the 162 registered diabetic patients can achieve goal of lipid level In this population, 9.7 percent (%) (n = 13) had a history of CVD. ApoB level in diabetic patients with and without CVD is 61.72 +/- 12.63 and 67.2 +/- 12.92 milligram per deciliter (mg/dL), respectively. Nearly ninety-eight percent of patients without cardiovascular diseases (CVD) have achieved apo B (< 90 mg/dL) goal, and 92.3% of patients with CVD have achieved apo B (< 80 mg/dL) goal. The two most commonly used lipid-lowering agents were statins and fibrates.
  
  
  CONCLUSIONS
  In patients with type 2 diabetes who achieved goal of LDL-c and non-HDL-c have also achieved apo B level. Thus, apo B measurement in addition to reached LDL-c and non-HDL-c targets may be not necessary especially in diabetic patients who did not previous CVD.
authors.affiliation: Endocrine Unit, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
authors.forename: Nattapol
authors.initials: N
authors.lastname: Sathavarodom
authors.forename: Apussanee
authors.initials: A
authors.lastname: Boonyavarakul
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001055:Apolipoproteins B / Q000097:blood*; D002318:Cardiovascular Diseases / Q000150:complications; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D058607:Fibric Acids / Q000008:administration & dosage; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents